Testosterone and 5-HT1A Agonist Dosing for Sexual Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for male and female sexual dysfunction, such as inhibited sexual desire, erectile dysfunction, and female sexual arousal disorders, lack effective alternatives and often have overlapping or interdependent disorders that are difficult to address independently.

Innovation Solution

The use of testosterone in combination with a 5-HT1A agonist, administered sublingually or through other rapid release methods, to create a short-lasting peak in free testosterone levels, coinciding with the peak effect of the 5-HT1A agonist, to enhance sexual arousal and desire, potentially with the inclusion of a PDE5 inhibitor for overlapping effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If testosterone is administered to treat inhibited sexual desire, then sexual desire is improved, but the treatment takes several hours to show effect

Engineering Contradiction:

Improveeffectiveness of sexual desire treatmentVSAvoidtime to achieve therapeutic effect

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by administering testosterone 3.5-5.5 hours before sexual activity, allowing the hormone to reach optimal plasma levels and prepare the physiological system in advance for sexual function, thereby ensuring reliable effectiveness while accounting for the delayed onset of testosterone action

Inventive Principle:

Principle #10Preliminary action

2Reliability

If a 5-HT1A agonist is administered one hour before sexual activity, then sexual arousal is enhanced, but the duration of action is limited

Engineering Contradiction:

Improveeffectiveness of sexual arousal treatmentVSAvoidduration of pharmacological effect

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent employs periodic action by timing the 5-HT1A agonist administration to create a peak effect window that coincides with the desired sexual activity period, using the predictable pharmacokinetic profile to achieve reliable arousal enhancement during the critical time frame

Inventive Principle:

Principle #19Periodic action

3Reliability

If testosterone and 5-HT1A agonist are administered at different times, then peak effects can be optimized, but treatment complexity increases

Engineering Contradiction:

Improveoptimization of peak effectsVSAvoidcomplexity of dosing regimen

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent resolves the complexity issue by establishing fixed preliminary administration times for each agent (testosterone 3.5-5.5 hours before, 5-HT1A agonist 1 hour before sexual activity), creating a standardized protocol that optimizes peak effect overlap while providing clear, manageable dosing instructions

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies dynamics by adjusting the administration timing of different agents to achieve dynamic overlap of their pharmacological effects, allowing the treatment to adapt to the temporal requirements of sexual function while maintaining a relatively simple two-agent regimen

Inventive Principle:

Principle #15Dynamics

Data Source

PatentEP2086544B1Use of testosterone and a 5-HT1a agonist in the treatment of sexual dysfunction

Publication Date: 2015.12.23 EB IP LYBRIDO BV

AI summary

The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.